Karyopharm Therapeutics reported $273.5M in Current Assets for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Acceleron Pharma XLRN:US $ 717.77M 19.84M
Amgen AMGN:US $ 19099M 2200M
AstraZeneca AZN:LN 27.27B 8.54B
Astrazeneca AZN:US 27.27B 8.54B
Avrobio Inc AVRO:US 233.52M 8.54M
Bristol Myers Squibb BMY:US $ 29161M 2050M
Eli Lilly And LLY:US $ 17295.5M 691M
Enanta Pharmaceuticals ENTA:US $ 321.15M 107.06M
Epizyme EPZM:US $ 272.49M 67.93M
GlaxoSmithKline GSK:LN 17.57B 958M
Karyopharm Therapeutics KPTI:US $ 273.5M 17.99M
Macrogenics MGNX:US $ 367M 7.72M
Mirati Therapeutics MRTX:US $ 1278.09M 25.42M
Nektar Therapeutics NKTR:US $ 1056.15M 42.9M
Novartis NOVN:VX 23.81B 1.61B
Novartis NVS:US $ 23808M 1610M
Regeneron Pharmaceuticals REGN:US $ 13337.6M 3282.5M
Sangamo Biosciences SGMO:US $ 554.06M 52.88M
Takeda 4502:JP Y 2476458M 236435M
Ultragenyx Pharmaceutical RARE:US $ 949.49M 121.44M
Xencor XNCR:US $ 480.97M 110.2M
YTE INCY:US $ 2620.06M 170.09M